Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Completed · Phase 1 · NCT04047862
Conditions: Locally Advanced and Metastatic Solid Tumors
At a glance
- Research payments reported, 2025
- $66,868
- U.S. investigators named
- 9
- Sites paid
- 6
- Planned or actual enrollment
- 446
About the trial
- Sponsor
- BeiGene
- Tested
- Ociperlimab (drug), Tislelizumab (drug), Pemetrexed (drug), Paclitaxel (drug), Nab paclitaxel (drug), Carboplatin (drug), Cisplatin (drug), Etoposide (drug), 5fluorouracil (drug), Oxaliplatin (drug), Capecitabine (drug)
- Dates
- Started 2019-08-15; completion 2024-08-07
- Results posted
- Yes
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1. Primary objective of Phase 1b was to assess overall response rate (ORR) determined by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 for patients in each dose-expansion cohort.
From ClinicalTrials.gov, last updated 2025-08-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $66,868 in research payments for this study in 2025 (21 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mohamad B. Sonbol, M.D. Hematology & Oncology · Scottsdale, AZ
- Jeffrey A. Bubis, DO Medical Oncology · Fleming Island, FL
- Eric M. Harris, D.O. Medical Oncology · Daytona Beach, FL
- Fadi Kayali, M.D. Medical Oncology · Sarasota, FL
- Jun Zhang, M.D., PH.D. Medical Oncology · Iowa City, IA
- Missak Haigentz, MD Medical Oncology · New Brunswick, NJ
- Rachel E. Sanborn, MD Medical Oncology · Portland, OR
- David R. Spigel, M.D. Medical Oncology · Nashville, TN
- Jonathan Thompson, M.D. Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Providence Portland Medical Center, OR $53,870
- The Medical College of Wisconsin, Inc. $6,652
- Rutgers, the State University $5,262
- Mayo Clinic Hospital, AZ $650
- Florida Cancer Specialist (scri) - Fort Myers $337
- University of Kansas Medical Center Research Institute, Inc. $96
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.